Skip to content
  • menu secondaire

    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts
    • Profile
      • About Transgene
      • Management Team
      • Board of Directors
      • Corporate governance
      • Ethics & compliance
      • Collaborations
      • Partners
    • Technology
      • Viral-based Immunotherapies
        • Therapeutic Vaccines
        • Oncolytic Viruses
      • myvac Platform
      • Invir.IO Platform
      • Publications and Presentations
    • Portfolio
      • Pipeline
      • TG4050
      • TG4001
      • TG6002
      • BT-001
      • Clinical trials FAQ
    • Press Releases
    • French

    Category: 2017

    Transgene Announces Financial Calendar for 2018

    20171221 Financial calendar 2018 EN

    Published 21 December 2017
    Categorized as 2017, Press release

    Transgene Announces Upcoming Investor Meetings

    20171218 PR financial agenda T1 18

    Published 18 December 2017
    Categorized as 2017, Press release

    BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors

    BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors

    Published 6 December 2017
    Categorized as 2017, Invir.IO, Press release

    Transgene successfully raises € 14.4 million from U.S. and European investors

    PR success ABB Transgene

    Published 10 November 2017
    Categorized as 2017, Press release

    Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017

    20171030 PR SITC TG4010

    Published 30 October 2017
    Categorized as 2017, Press release

    First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma

    20171026-PR-TG6002

    Published 26 October 2017
    Categorized as 2017, Press release, TG6002, TG6002

    TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B

    20171023 PR post AASLD TG1050 final. docx

    Published 23 October 2017
    Categorized as 2017, Press release, TG1050, TG1050

    Third Quarter Marked by Progress in Clinical Development and Research

    171019 PR Q3-2017 FINAL

    Published 19 October 2017
    Categorized as 2017, Press release

    Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

    20171017 PR AASLD TG1050 final

    Published 17 October 2017
    Categorized as 2017, Press release, TG1050, TG1050

    Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

    Caroline Tosch, et al. Journal for ImmunoTherapy of Cancer, 2017, 5:70 – Download the article Publication

    Published 12 October 2017
    Categorized as 2017, Publication, TG4010

    Posts navigation

    Page 1 … Page 5 Older posts
    • Investors
    • Careers
    • Terms of Use
    • privacy policy
    • Cookie policy
    • Contacts

    Transgene sa
    400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
    67405 Illkirch Graffenstaden Cedex - France |
    Tel. : + 33 (0) 3 88 27 91 00

     

    © 2021 Transgene - All rights reserved
    Credits

    This Website uses cookies to provide you with the most relevant experience. By clicking on the "Accept All" button, you agree to the deposit of all cookies on your terminal. You can change your preferences or withdraw your consent at any time by clicking on the "Settings" button.
    More informationSettings Decline all ACCEPT ALL
    Cookies

    Privacy Overview

    This website uses cookies to improve your experience while you browse the website. Of these, cookies categorized as necessary are stored on your browser as they are essential for the functioning of basic functionalities of the website. We also use third-party cookies which advise us to analyze and understand how you use this website. These cookies will only be stored in your browser with your consent. You also have the option of deactivating these cookies. But disabling some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. Analytical cookies used to understand how visitors interact with the website.
    Functional (video)
    Functional cookies help to perform certain functions such as sharing website content on social media platforms, collecting feedback and other third-party functionality.
    Third-party application cookies (twitter)
    Cookies déposés par des sociétés autres que Transgene. Ces cookies sont susceptibles de transmettre aux sociétés tiers des informations en lien avec les pages consultées. Ces sociétés doivent s’engager à garder ces données confidentielles dans le cadre de la loi informatique et libertés (6 janvier 1978).
    Save & Accept
    Powered by CookieYes Logo